PMID- 9815630
OWN - NLM
STAT- MEDLINE
DCOM- 19990303
LR  - 20071114
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 3
IP  - 12 Pt 1
DP  - 1997 Dec
TI  - Toward the validation of aneusomy detection by fluorescence in situ hybridization 
      in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical 
      features predicts recurrence and defines clinical testing limitations.
PG  - 2317-28
AB  - Fluorescence in situ hybridization (FISH) is regarded as a potential new tool for 
      the clinical management of bladder cancer that works by detecting cytogenetic 
      aberrations in noncycling, exfoliated cells from bladder irrigations. However, 
      clinical validation steps must be addressed to define the true predictive 
      potential in a clinical setting. Toward the validation of FISH with the use of 
      bladder washings and prior to incorporation into a large, prospective clinical 
      trial, a pilot study was designed to determine its clinical potential, define 
      testing limitations, optimize a panel of probes specific for bladder cancer 
      detection, and outline protocol/data collection parameters. Correlations with 
      standard cytogenetics and clinicopathological features of bladder cancer were 
      investigated. Exfoliated cells obtained from benign bladder washings served as 
      normal controls. The results of this pilot study suggest the following: (a) FISH 
      and cytology are complementary testing procedures; however, the FISH data 
      provided valuable ploidy and specific genotypic information for recurrent tumors 
      in "suspicious" cases; (b) chromosomal aberrations defined by FISH are associated 
      with tumor grade and stage (i.e., simple numerical aberrations were associated 
      with low-grade tumors, and high-grade and invasive tumors exhibited multiple, 
      nonrandom chromosomal aberrations and vast intratumor heterogeneity); (c) somatic 
      pairing or homologous centromeric association can give a false-positive result 
      and appears to be linked to prior therapy; (d) dual hybridization with reference 
      gene-specific probes must be used to control for somatic pairing; and (e) focal, 
      deep muscle invasive lesions, with no surface exposure, may yield false-negative 
      results. The data suggest that FISH analysis, with the use of cells isolated from 
      bladder washings, is a powerful technique holding promise for early cancer 
      detection, monitoring treatment outcome, and predicting recurrence of disease.
FAU - Zhang, F F
AU  - Zhang FF
AD  - Departments of Cytogenetics, City of Hope National Medical Center, Duarte, 
      California 91010, USA.
FAU - Arber, D A
AU  - Arber DA
FAU - Wilson, T G
AU  - Wilson TG
FAU - Kawachi, M H
AU  - Kawachi MH
FAU - Slovak, M L
AU  - Slovak ML
LA  - eng
GR  - CA-33572/CA/NCI NIH HHS/United States
GR  - CA32102/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
SB  - IM
MH  - *Aneuploidy
MH  - *Chromosome Aberrations
MH  - *Chromosome Disorders
MH  - Cytogenetics/methods
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Karyotyping
MH  - Male
MH  - Neoplasm Staging
MH  - Sex Chromosome Aberrations
MH  - Tumor Cells, Cultured
MH  - Urinary Bladder/cytology/pathology
MH  - Urinary Bladder Neoplasms/*genetics/*pathology
MH  - Y Chromosome
EDAT- 1998/11/17 00:00
MHDA- 1998/11/17 00:01
CRDT- 1998/11/17 00:00
PHST- 1998/11/17 00:00 [pubmed]
PHST- 1998/11/17 00:01 [medline]
PHST- 1998/11/17 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1997 Dec;3(12 Pt 1):2317-28.